Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform
Two VC Mega-Deals Revealed In Mid-August
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
